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Abstract
Bloodstream infections (BSIs) caused by Klebsiella pneumoniae carbapenemases (KPC)-producing K. pneumoniae (KPC-KP) are associ-
ated with high mortality rates. We investigated outcomes, risk factors for mortality and impact of appropriate antimicrobial treatment
in patients with BSIs caused by molecularly conﬁrmed KPC-KP. All consecutive patients with KPC-KP BSIs between May 2008 and May
2010 were included in the study and followed-up until their discharge or death. Potential risk factors for infection mortality were exam-
ined by a case-control study. Case-patients were those who died from the BSI and control-patients those who survived. Appropriate
antimicrobial therapy was deﬁned as treatment with in vitro active antimicrobials for at least 48 h. A total of 53 patients were identiﬁed.
Overall mortality was 52.8% and infection mortality was 34%. Appropriate antimicrobial therapy was administered to 35 patients; mor-
tality due to infection occurred in 20%. All 20 patients that received combination schemes had favourable infection outcome; in con-
trast, seven of 15 patients given appropriate monotherapy died (p 0.001). In univariate analysis, risk factors for mortality were age
(p <0.001), APACHE II score at admission and infection onset (p <0.001) and severe sepsis (p <0.001), while appropriate antimicrobial
treatment (p 0.003), combinations of active antimicrobials (p 0.001), catheter-related bacteraemia (p 0.04), prior surgery (p 0.014) and
other therapeutic interventions (p 0.015) were signiﬁcantly associated with survival. Independent predictors of mortality were age,
APACHE II score at infection onset and inappropriate antimicrobial treatment. Among them, appropriate treatment is the only modiﬁ-
able independent predictor of infection outcome.
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Carbapenems have been widely used as treatment of choice
for serious infections caused by ESBL producers, exerting
selection pressure for carbapenem resistance [1]. Carbape-
nem-resistant bacteria have been therefore disseminated and
attained high prevalence rates in some regions [2,3].
Klebsiella pneumoniae carbapenemases (KPC)-type
enzymes are emerging resistance determinants, especially for
K. pneumoniae [2,4]. During the last decade, a rapidly evolv-
ing spread of KPC b-lactamases has been documented
worldwide, creating an endemic situation in the United
States, Israel and more recently in Greece [3–6].
Carbapenem resistance among K. pneumoniae isolates rep-
resents a major public health issue in Greek hospitals, with
resistance rates of up to 37% (EARSS results at http://
www.rivm.nl/earss/result) mainly due to the dissemination of
VIM-type carbapenemases [2,3,7]. Furthermore, since late
2007, a nationwide spread of KPC enzymes has been docu-
mented, creating an emerging concern [5,6].
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KPC-associated infections are predominantly nosocomial
and systemic infections, affecting patients with multiple risk
factors [4,8]. Therapeutic failures and adverse impact on
patient outcome, with high mortality rates ranging from 22%
to 57%, have been reported [2]. The antimicrobial treatment
options are usually limited to colistin and tigecycline [2,4].
The optimal treatment for infections caused by KPC-produc-
ing bacteria has not yet been established [9]. Many descrip-
tive studies have focused on outbreaks caused by KPC
producers, especially in endemic regions. However, data
regarding the success rates of different treatment regimens
and patient outcomes are still limited.
We present the results of a prospective observational
cohort study regarding outcomes, risk factors for mortality
and impact of appropriate antimicrobial treatment of blood-
stream infections (BSIs) caused by KPC-producing K. pneumo-
niae (KPC-KP).
Materials and Methods
Study setting, patient population and study design
The study was conducted in Tzaneio General Hospital,
Piraeus, Greece, a 480-bed tertiary care hospital having
approximately 32 000 admissions each year, and two inten-
sive care units (ICU): a ten-bed general ICU (medical and
surgical) and a ten-bed cardiology ICU.
The study population included all consecutive patients with
BSIs (documented by at least one positive blood culture and
clinical presentation consistent with bacteraemia) caused by
KPC-KP between May 2008 and May 2010. Only the ﬁrst epi-
sode per patient was included in our analysis. Patients with
polymicrobial bacteraemia were excluded. All patients were
followed-up until their discharge or death. The study was
observational; administration of antimicrobials and other ther-
apeutic decisions were controlled by patients’ physicians in
collaboration with infectious disease specialists. A case-control
study was conducted between patients who died from BSI
(case-patients) and those who survived (control-patients), to
detect risk factors associated with infection mortality. We did
not include a control group of patients harbouring carbape-
nemase-negative K. pneumoniae, which are rarely isolated in
critically ill patients in our institution; only ﬁve BSIs due to such
isolates were recorded in our ICU during the study period.
Abstraction of patients’ data
Medical records of patients who met the study criteria were
reviewed twice a week. Parameters assessed included (i)
demographics (age and gender), (ii) ward and duration of hos-
pitalization at isolation, (iii) clinical characteristics, (iv) comor-
bidities; (v) invasive procedures (mechanical ventilation, central
venous catheter, surgical operations after admission and other
interventions), (vi) nosocomial environment exposures (admis-
sion from other hospital, prior hospitalization and ICU stay,
prior surgery and previous long-term care facility residency),
(vii) antimicrobial chemotherapy for current infection, (viii)
therapeutic intervention targeting the removal of the probable
focus of the infection, such as catheter removal, debridement,
drainage or other surgical procedures, and (ix) outcomes
(overall in-hospital mortality and infection mortality).
Deﬁnitions
BSI onset was deﬁned as the date of collecting the ﬁrst
blood culture yielding study isolate. The probable source
(urinary, respiratory, vascular, catheter-related, soft-tissue
and primary bacteraemia) was determined on the basis of
microbiological results and physicians’ ﬁndings according to
CDC deﬁnitions [10]. Catheter-associated BSI was detected
by cultures of catheter tips and differential time to positivity.
Septic shock was deﬁned as sepsis associated with organ dys-
function and accompanied by persistent hypotension despite
volume replacement. Severity of illness on admission and on
infection onset was assessed with the APACHE II score [11].
Appropriate empirical antimicrobial treatment referred to
administration of in vitro active antimicrobials against the
study isolates, within £24 h from infection onset. Appropri-
ate deﬁnitive treatment was considered the administration of
in vitro active antibiotics for at least 48 h [12].
Overall mortality included all causes of death during hospi-
talization. Infection mortality was deﬁned as death mainly
attributed to the BSI episode, substantiated by severe sepsis
or septic shock and/or multiorgan dysfunction due to the
KPC-KP BSI. The possible contribution of the BSI to death
was judged by two independent reviewers. The microbiologi-
cal outcome was classiﬁed according to the following deﬁni-
tions: (i) response, study isolate absent in repeat blood
cultures obtained during or after the course of antimicrobial
therapy; (ii) failure, study isolate present in repeated blood
cultures obtained at least 48 h after the treatment initiation;
and (iii) indeterminate, repetitive specimens not available for
evaluation of microbiological outcome.
Microbiology
Blood cultures were incubated using the BACTEC 9240
Automated Blood Culture System (Becton and Dickinson,
Franklin Lakes, NJ, USA). Identiﬁcation and susceptibility test-
ing of K. pneumoniae blood isolates were performed by the
Vitek 2 automated system (bioMerieux, Marcy l’ Etoile,
France). Colistin and tigecycline MICs were also determined
by the CLSI reference broth microdilution method [13]. For
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tigecycline, the US Food and Drug Administration recom-
mendation was used (susceptible, MIC £ 2 mg/L; resistant,
MIC ‡ 8 mg/L) [14], and for colistin, the EUCAST clinical
breakpoints for Enterobacteriacae were applied (susceptible,
MIC £ 2 mg/L; resistant, MIC > 2 mg/L; available at http://
www.eucast.org/clinical_breakpoints/).
Screening for phenotypic detection of carbapenemases
was performed for all isolates exhibiting reduced susceptibil-
ity to carbapenems (MIC > 1 mg/L) by using the modiﬁed
Hodge test, the combined disk test with imipenem and
EDTA [15], and the combined boronic acid disk tests per-
formed as described previously [16]. The presence of the
blaKPC gene and other broad-spectrum b-lactamase genes
(ESBLs, plasmidic AmpCs and MBLs) was detected by poly-
merase chain reaction (PCR) and sequencing [5].
Surveillance cultures
All patients hospitalized in a general ICU or directly transferred
from other institutions to hospital wards were screened for
rectal colonization with KPC-KP at admission and once a week
during their hospitalization. Rectal swabs were directly plated
on MC agar with the addition of 10 lg ertapenem disks [17]
and suspected colonies were phenotypically tested for carbape-
nemase production as described above.
Statistical analysis
Values were expressed as means ± standard deviation (contin-
uous variables) or percentages of the group from which they
were derived (categorical variables). The normality of distribu-
tions was assessed by the Kolmogorov–Smirnov test. Continu-
ous variables were compared by the Student t-test or the
Mann–Whitney U-test, as appropriate. Categorical variables
were evaluated by using the chi-square test or Fisher’s exact
test, as required. Odds ratios (ORs) and 95% conﬁdence
intervals (CIs) were calculated; two-tailed tests were used to
determine statistical signiﬁcance and p value £0.05 was con-
sidered signiﬁcant. Multivariate analysis was used to identify
independent predictors of infection mortality by applying
logistic regression. Variables with p value £0.05 in univariate
testing were incorporated into the model using a forward
stepwise approach. A p value £0.05 was set as the limit for
retaining the variables in the model. Statistical analyses were
performed by using the SPSS statistical software (version 17;
SPSS Inc., Chicago, IL, USA).
Results
A total of 53 patients with BSI caused by KPC-KP were iden-
tiﬁed during the study period. Most of the patients (38,
71.7%) were hospitalized in the general ICU, while 13 were
hospitalized in medical and two in surgical wards, respec-
tively. The probable source of bacteraemia was identiﬁed in
30 patients (central venous catheters, 12 patients; respira-
tory tract, 7; urinary tract, 6; skin or soft tissue, 4; central
nervous system, 1 patient), while a source was not detected
in the remaining 23 patients. Patients’ demographic and clini-
cal characteristics and data for nosocomial environment
exposure are presented in Table 1.
Susceptibility testing showed that 40 (75.5%) KPC-KP were
susceptible to colistin, 45 (89.9%) to tigecycline, 51 (96.2%)
to gentamicin and 21 (39.6%) to meropenem. It should be
noted that most isolates would have been classiﬁed as me-
ropenem resistant if the CLSI June 2010 updated breakpoints
were available during the study period [18]. All isolates were
phenotypically identiﬁed as possible KPC-KP by positive
modiﬁed Hodge test, negative EDTA disk test and positive
boronic acid disk test. By PCR all 53 isolates were found to
carry blaKPC allele, 46 of them blaSHV and 4 blaCTX-M, shown
by sequencing to be blaKPC-2, blaSHV-12 and blaCTX-M-15,
respectively.
Outcomes of the 53 patients with KPC-KP BSI are shown
in Table 2. Infection mortality was lower among ICU patients
(28.9%) vs. non-ICU patients (46.7%, p 0.22), probably due
to closer monitoring of ICU patients. The mean time from
BSI onset to death was 7.3 days.
Appropriate antimicrobial treatment, which lasted at least
48 h, was administered to 35 patients. Infection mortality in
the appropriately treated patients was 20%, being signiﬁcantly
lower than infection mortality of patients who did not
receive appropriate treatment (61.1%, p 0.003). Appropriate
empirical treatment was administered to 14 patients (seven
with severe sepsis) and infection mortality among them was
similar to that of patients who did not receive appropriate
empirical treatment (35.7% vs. 33.3%, p 0.87). Timely initia-
tion of active antimicrobials (within 3 days) was noted for 17
of the 35 patients who received appropriate antimicrobial
treatment, with no signiﬁcant impact on patient survival
(infection mortality 23.5% vs. 16.7%, p 0.69). Combination
schemes were received by 20 appropriately treated patients
and all of them survived. In contrast, infection mortality
among 15 patients administered monotherapy, mainly colistin
or tigecycline, was signiﬁcantly higher (46.7%, p 0.001). The
most common treatment regimen was the combination of
colistin with tigecycline, received by nine patients. Colistin
was used as monotherapy in seven patients with infection
mortality 66.7%, while tigecycline monotherapy was adminis-
tered to ﬁve patients with infection mortality 40% (Table 3).
In the univariate analysis, several factors were signiﬁcantly
associated with infection mortality (Table 1). Patients who
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survived were signiﬁcantly younger (p <0.001) and more
often had prior ICU-hospitalization (p 0.06), prior surgical
operations (p 0.014) and central venous catheters at isola-
tion time (p 0.014). Catheter-related bacteraemia was signiﬁ-
cantly associated with survival (p 0.04). APACHE II scores at
admission and at infection onset were signiﬁcantly higher
among non-survivors (p <0.001). Presentation with severe
sepsis or septic shock was also signiﬁcantly associated with
infection mortality (p <0.001). Appropriate antimicrobial
treatment (p 0.003), combination schemes (p 0.001) and
other therapeutic interventions targeting the removal of the
focus of infection (p 0.015) were strongly correlated with
survival.
The results of the ﬁnal multivariate model are shown in
Table 4. Patient’s age, APACHE II score at infection onset
and inappropriate antimicrobial therapy were independent
predictors of infection mortality. To further evaluate the
impact on survival of the appropriate antimicrobial
TABLE 1. Univariate analysis of factors associated with infection mortality for 53 patients with bloodstream infections caused







n = 18 OR (95% CI) p
Patient-related
Age, years 63.8 ± 19.9 56.7 ± 20.9 77.5 ± 5.9 NA <0.001
Male sex 33 (62.3) 21 (60.0) 12 (66.7) 1.33 (0.40–4.39) 0.64
Comorbidities >2 28 (52.8) 16 (45.7) 12 (66.7) 2.38 (0.73–7.76) 0.15

























Presence of CVC 45 (84.9) 33 (94.3) 12 (66.7) 0.12 (0.02–0.69) 0.014
Admission from other hospital 21 (39.6) 17 (48.6) 4 (22.2) 0.30 (0.08–1.10) 0.08
Prior hospitalization 37 (69.8) 25 (71.4) 12 (66.7) 0.80 (0.24–2.72) 0.72
Prior ICU stay 16 (30.2) 14 (40.0) 2 (11.1) 0.19 (0.04–0.95) 0.06
Prior surgery 34 (64.2) 27 (77.1) 7 (38.9) 0.19 (0.06–0.65) 0.014
APACHE II score at admission 21.0 ± 7.3 18.2 ± 5.6 26.6 ± 7.3 NA <0.001
APACHE II score at infection onset 21.1 ± 8.2 17.6 ± 5.7 28.0 ± 7.8 NA <0.001
Prior colonization 29 (54.7) 21 (60.0) 8 (44.4) 0.53 (0.17–1.68) 0.28
Infection- and isolate-related
primary bacteraemia 23 (43.4) 12 (34.3) 11 (61.1) 3.01 (0.93–9.77) 0.06
Catheter-related bacteraemia 12 (22.6) 11 (31.4) 1 (5.6) 0.13 (0.01–1.09) 0.04
Severe sepsis or septic shock 21 (39.6) 7 (20.0) 14 (77.8) 14 (3.50–55.98) <0.001
Meropenem MIC > 4 32 (60.4) 24 (68.6) 8 (44.4) 0.37 (0.11–1.18) 0.09
Presence of colistin resistance 13 (24.5) 10 (28.6) 3 (16.7) 0.50 (0.12–2.11) 0.50
Elevated MICs of tigecycline 8 (15.1) 5 (14.7) 3 (16.7) 1.20 (0.25–5.71) 1.00
Treatment-related
Appropriate empirical treatment 14 (26.4) 9 (25.7) 5 (27.8) 1.11 (0.31–3.99) 0.87
Appropriate antimicrobial treatment 35 (66.0) 28 (80.0) 7 (38.9) 0.16 (0.04–0.56) 0.003
Initiation of active antimicrobials within 3 daysa 17 (48.6) 13 (46.4) 4 (57.1) 1.54 (0.29–8.18) 0.69
Combination of active antimicrobialsa 20 (57.1) 20 (71.4) 0 (0) NA 0.001
Other therapeutic interventions 18 (34.0) 16 (45.7) 2 (11.1) 0.15 (0.03–0.74) 0.015
Data are presented as n (%) or mean ± standard deviation (SD).
aFor patients that received appropriate antimicrobial treatment.
OR, odds ratio; CI, conﬁdence interval; ICU, intensive care unit; CVC, central venous catheter; APACHE II score, acute physiology and chronic health evaluation II score;
NA, non-applicable.
TABLE 3. Appropriate antimicrobial treatment for at least
48 h and infection mortality
Treatment for infection n (%) Infection mortality n (%)
Combination schemes 20 (57.1) 0
Tigecycline combined with
Colistin 9 (26.5) 0
Gentamicin 3 (8.8) 0
Colistin + carbapenem 2 (5.9) 0
Carbapenem 1 (2.9) 0
Colistin + gentamicin 1 (2.9) 0
Amikacin 1 (2.9) 0
Colistin + gentamicin 2 (5.8) 0
Carbapenem + gentamicin 1 (2.9) 0
Monotherapy 15 (42.9) 7 (46.7)
Colistin 7 (20) 4 (66.7)
Tigecycline 5 (14.7) 2 (40)
Gentamicin 2 (5.9) 0
Carbapenem 1 (2.9) 1 (100)
Total 35 7 (20)
TABLE 2. Outcomes of the 53 patients with bloodstream
infections caused by KPC-producing K. pneumoniae
Outcomes n (%)
Patient outcome
Overall mortality 28 (52.8)
14-day mortality (all reasons) 15 (28.3)
Infection outcome
Infection mortality 18 (34)
Days from infection to death, mean ± SD 7.3 ± 5.7
Microbiological outcome
Microbiological response 29 (54.7)
Microbiological failure 15 (28.3)
Indeterminate 9 (17.0)
SD, standard deviation.
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treatment, a second multivariate model was built by retaining
appropriate antimicrobial treatment adjusted by the more
signiﬁcant potential confounders, age, APACHE II at infection
onset, severe sepsis or septic shock and other therapeutic
interventions. No signiﬁcant differences were observed
between these two models (data not shown), underlining the
importance of appropriate antimicrobial treatment.
Discussion
The global spread of KPC-KP poses remarkable clinical and
therapeutic challenges. The increasing prevalence of severe
KPC infections, with high mortality rates, underlines the
need for effective treatment [2,9]. However, the optimal
treatment for infections caused by KPC-producing bacteria
has not yet been determined. Although several studies have
described outbreaks caused by KPC producers, there is a
scarcity of data to provide therapeutic recommendations
based on clinical evidence from well-deﬁned prospective
studies [9].
Our study involved a series of 53 patients with KPC-BSI.
The clinical proﬁle of the patients was similar to that
reported in other studies of KPC-KP infections [2,8]. Half of
our patients were colonized by KPC-KP prior to the BSI; a
similar colonization rate was observed in another study [6].
The previously reported high rate of subsequent clinical
infection among silent carriers highlights the value of active
surveillance [19]. Information about colonization status apart
from infection control beneﬁts is crucial for the choice of
empirical treatment in septic patients.
The overall mortality in our patients was high (52.8%),
similar to that observed in other studies [6,20–22], probably
reﬂecting critical status as measured by the APACHE II score
at admission. The infection mortality in our cohort (34%),
exclusively including patients with BSI, was also relatively
high. However, the 14-day mortality rate (28.3%) was lower
than that reported previously among 19 patients with KPC-
KP bacteraemia (47%) [20].
To further investigate the KPC-KP infection mortality, we
evaluated the inﬂuence of patient, isolate and infection
characteristics, along with therapeutic interventions, on infec-
tion mortality. These parameters were assessed in patients
who died from compared with those who survived KPC-KP
BSI; this approach was mainly intended to identify speciﬁc
factors associated with the infection mortality and possibly
highlight implications for the management of these infections.
Appropriate antimicrobial treatment had a signiﬁcant impact
on patient outcome. In contrast, appropriate empirical treat-
ment and initiation of active antimicrobials within 3 days was
not associated with favourable infection outcome; this ﬁnding
could possibly be explained by the more frequent presenta-
tion with severe sepsis in this subgroup. In the single previ-
ous report on the impact of antimicrobial and adjunctive
therapies on outcomes, receipt of antibiotics with in vitro
activity against KPC-KP was not associated with patient sur-
vival [23]. Our study also demonstrated a superiority of
combination treatment. Tigecycline with colistin was the
most common combination scheme; its effectiveness is sup-
ported by recently published time-kill results [24]. It is of
note that infection mortality among patients who received
colistin monotherapy is similar to that in those who received
inappropriate antimicrobial treatment. Apart from the non-
favourable outcome of colistin-treated patients, colistin resis-
tance has also emerged in our settings [25], suggesting that
colistin monotherapy should be given with caution. Regarding
carbapenems, frequent clinical and microbiological failures
were observed previously when KPC infections caused by
carbapenem-susceptible isolates were treated with carbape-
nem monotherapy [26].
A non-identiﬁable source of bacteraemia was correlated
with poor outcome, almost reaching statistical signiﬁcance,
while catheter-related bacteraemia was signiﬁcantly associ-
ated with survival. These ﬁndings suggest the importance of
interventions targeting the focus of infection, which were sig-
niﬁcantly correlated with survival. Adjunctive therapies were
also independently associated with survival in other reports
[23].
Older age and higher APACHE II score at admission and
at infection onset, along with presentation with severe sepsis
or septic shock, were the main predictors of infection mor-
tality. Unexpectedly, prior hospitalization in an ICU was
associated with favourable infection outcome. It could be
suggested that a prior ICU stay led to more effective empiri-
cal treatment due to high clinical suspicion for carbapenem-
ase producers, which are common in Greek ICUs [2].
Overall, it is evident that KPC-KP BSIs are associated with
high mortality rates. According to the results of the multivar-
iate analysis, the major predictors of infection mortality were
severity of the baseline condition, older age and inappropri-
ate treatment. Among them, the only modiﬁable variable that
TABLE 4. Multivariate analysis of factors associated with
infection mortality for 53 patients with bloodstream infec-
tion caused by KPC-producing K. pneumoniae
Variable OR (95% CI) p
APACHE II score at infection onset 1.26 (1.04–1.53) 0.021
Age 1.21 (1.02–1.44) 0.029
Appropriate antimicrobial treatment 0.05 (0.003–0.74) 0.030
APACHE II score, acute physiology and chronic health evaluation II score.
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could be used to improve outcomes is the administration of
appropriate treatment. It is thus critical, further to infection
control strategies, to identify patients at risk of adverse
outcome and ensure effective treatment based on sufﬁcient
evidence.
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